Navigation Links
Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
Date:9/22/2008

Results and Preclinical Research at Upcoming Conferences

CALGARY, Sept. 22 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) today announced the participation of five of its collaborators and their schedule of presentations at four conferences through November 15, 2008 covering clinical trial results and preclinical research on REOLYSIN(R).

"It's an important time for Oncolytics as we begin to share additional results of our ongoing clinical trial and preclinical research programs for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is the results of these trials that should help us to determine the late-stage clinical path forward for REOLYSIN(R)."

Dr. Kevin Harrington and colleagues are scheduled to present a poster presentation entitled "Phase I Trial of Oncolytic Reovirus (Reolysin) in Combination with Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers" at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting, being held in San Diego, California from October 31-November 2, 2008.

Prof. Hardev Pandha and colleagues are scheduled to present a poster presentation entitled "A Phase I Study to Evaluate the Feasibility, Safety, and Biological Effects of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel to Patients with Advanced Malignancies" at the iSBTc annual meeting.

Dr. Monica Mita et al is scheduled to make two oral presentations, both entitled "A Phase II Study of Intravenous Reolysin (Wild Type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" at the Chemotherapy Foundation Symposium XXVI, being held in New York from November 4-8, 2008 and also at the Connective Tissue Oncology Society (CTOS) meeting, being held in London, U.K. from November 13-15, 2008.

Dr. Anders Kolb and colleagues are scheduled to deliver a poster presentation ent
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)... The Vanuatu National Advisory Commit...ational Communication (SNC) Project in collaborati...IMsystems Ltd. of New Zealand have generated preli...hat will form the background for the country&rsquo...onvention on Climate Change (UNFCCC). , ...
(Date:11/27/2009)... , DURHAM, N.C., Nov. 27 Cromoz...tiate water-soluble carbon nanotube-based cancer d...-soluble carbon nanotubes, which have functional g...h cancer drugs, was developed in partnership with ...ed carbon nanotubes serves as a drug delivery vehi...
(Date:11/27/2009)... PARIS, November 27 S...market Oralair(R) in both adults and children,thro...irst country where,Oralair(R) has been marketed, w...R) is now registered in Austria, Belgium, Bulgaria...many, Greece, Hungary, Ireland, Italy,Latvia, Lit...
(Date:11/27/2009)... A mechanised blue dye test alternat...ging quality assurance one step closer for pharma-...eak testing machine developed by Sepha for use ...ed in several local and global pharma-companies su...uality assurance and productivity improvements on ...
Breaking Biology Technology:Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3
..., Allora Aguilera, Chate Luu, Ivan Huang,Diana ...is Simonyi, Jim Wong, Quan Nguyen , , ...000 Alfred Nobel Drive, , Hercules, CA 94...r at The American Society for Cell Biology , ...CA , , , , , ...
..., PhD, Aiguo Zhang, PhD, Chloe Etienne, Ivan Huang... 2000 Alfred Nobel Drive,Hercules, CA 94547 USA...Bio-Plex cytokine assays are bead-based multiplex ...ns of analytes in a Bio-Plex cytokine immunoassay ...standard curve. More specifically, , a se...
...ted by Dr. Ivan Kaiser, University of Wyoming,L..., Dr. Ivan Kaisers research involves the is...om snake venom, such as post-synaptic neurotoxins ... research, Dr. Kaiser teaches a course on protein ...he principles of protein purification , u...
Other Biology Technology:Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 2Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 3Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 4Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 5Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 6Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 7Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B 8
(Date:11/26/2009)... are some of the Ocean,s most distinctive resident...s strange head shape, says Michelle McComb from F... the shark,s vision. ,Perhaps their visual field h...McComb, giving the sharks excellent stereovision a... there were two schools of thought on this theory....
(Date:11/26/2009)...impressive antlers, red deer have been caught in t...ntlers are much more than decorative. They are let...g. John Currey, from The University of York, UK, h...bone for over half a century and has become fascin...h a long-standing collaboration with Tomas Landete...
(Date:11/26/2009)...t last worked out a way of using recordings of bir...ations. This is the first time sound recordings fr...curate estimates of bird species, populations. Bec...ological Society,s Journal of Applied Ecology , w...major advance in our ability to monitor whale and ...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2Tough yet stiff deer antler is materials scientist's dream 2Ecologists sound out new solution for monitoring cryptic species 2New NIST trace explosives standard slated for homeland security duty 14912 1New NIST trace explosives standard slated for homeland security duty 14912 2AmeriCares and Boeing Deliver Emergency Relief Supplies to the Philippines 61675 1AmeriCares and Boeing Deliver Emergency Relief Supplies to the Philippines 61675 2Universal Health Services Inc Announces Stock Split and Cash Dividend Increase 61672 1
... we put in our heads" The answer: a lot. For start... And then there are all the little details that st...ime we spilled orange juice on our test back in th...or some of us). , So where do we put it all" If w...e easy: we would store memories as 0s and 1s. But ...
...ified that increases the risk of two chronic, auto... (RA) and systemic lupus erythematosus (lupus). Th...aboration between the Intramural Research Program ...usculoskeletal and Skin Diseases (NIAMS) and other...itutes of Health. , These results appear in the S...
...Childrens Hospital will receive the largest resear...ar, eleven-part grant awarded by the National Inst...23.7 million grant will support the Northwest Geno...nberg, MD, of Seattle Childrens Hospital Research ...shington School of Medicine (UWSOM) and Fred Hutch...
Other Biology News:A balanced memory network 2Study identifies genetic risk factor for rheumatoid arthritis, lupus 2Study identifies genetic risk factor for rheumatoid arthritis, lupus 3Seattle Children's Hospital leads $23.7 million NIH grant to study gene repair 2Seattle Children's Hospital leads $23.7 million NIH grant to study gene repair 3
Sheep Anti-chk 1 kinase Polyclonal Antibody, Unconjugated from Exalpha Biologicals, Inc.
... The Human Neural Stem Cell Functional Identificat...ments, which can be used for the short-term mainte...the induction of NSCs into astrocyte, neuron and o...ing of mouse anti-human Nestin, mouse anti-human G...
Rat Anti-Kinase Suppressor Of Ras Monoclonal Antibody, Unconjugated, Clone MINT/1/4 from GeneTex
Mouse Anti-NY-ESO-1 Monoclonal Antibody, Unconjugated, Clone E978 from Upstate
Biology Products: